Emerald Bioscience (OTCMKTS:EMBI) Stock Price Up 10.1% – Time to Buy?

Emerald Bioscience Inc. (OTCMKTS:EMBIGet Free Report)’s share price was up 10.1% on Wednesday . The company traded as high as $0.54 and last traded at $0.5194. 335,342 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.4717.

Emerald Bioscience Trading Up 10.1%

The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.43. The stock has a market cap of $139.24 million, a P/E ratio of -6.49 and a beta of 0.43. The firm’s 50 day simple moving average is $0.67.

Emerald Bioscience Company Profile

(Get Free Report)

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.

See Also

Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.